ANIX — Anixa Biosciences Balance Sheet
0.000.00%
- $91.79m
- $75.41m
- 22
- 13
- 79
- 31
Annual balance sheet for Anixa Biosciences, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 35.7 | 29.7 | 23.8 | 19.9 | 15.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 0.27 | 0.173 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 36 | 30.2 | 25.4 | 21.4 | 15.9 |
| Net Property, Plant And Equipment | 0.254 | 0.212 | 0.166 | 0.229 | 0.193 |
| Other Long Term Assets | |||||
| Total Assets | 36.3 | 30.4 | 25.5 | 21.6 | 16.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.27 | 2.04 | 2.03 | 2.5 | 1.97 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.82 | 1.36 | 1.19 | 1.59 | 0.919 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 35.4 | 29 | 24.3 | 20 | 15.2 |
| Total Liabilities & Shareholders' Equity | 36.3 | 30.4 | 25.5 | 21.6 | 16.1 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |